

© Copyright – 台灣PSP/CBS研究聯盟 | design by Morcept
PSP
Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disease, classified symptoms as an atypical Parkinsonian syndrome. The onset age of typically begins between the ages of 60 and 70. Unlike Parkinson’s disease, where the pathogenic protein is α-synuclein accumulation, PSP involves the deposition of four-repeat tau protein within neurons and gial cells in the brain.
Prevalence studies have shown that for every 100 patients with parkinsonian features, 2 to 5 will have PSP.
Compared to typical Parkinson’s disease, PSP progresses more quickly. In the early stages, patients often fall due to poor balance and reflexes. Eye movement is restricted, especially when looking up or down, and other symptoms resemble those of Parkinson’s disease, including limb rigidity, coordination problems, speech disorders, and swallowing difficulties. PSP patients generally show a poorer response to Levodopa compared to people with typical Parkinson’s disease, and may experience early personality changes such as becoming withdrawn, less talkative, or conversely, emotionally unstable, with symptoms like depression, anxiety, and cognitive impairment.
The diagnosis of PSP involves clinical interviews, medical history, and neurological exams, with a particular focus on eye movement problems. Brain imaging techniques, including positron emission tomography (PET) scans for Tau, and abnormal Tau aggregation changes in cerebrospinal fluid, have become novel diagnostic tools in recent years. Currently, treatment remains limited to dopamine supplementation and regular exercise, which are essential. Clinical trials targeting the underlying mechanisms of PSP are currently ongoing.